| Autor: |
SHANG Di, SUN Dongyan, CHEN Yanling, JIANG Zhihe |
| Jazyk: |
čínština |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Zhongliu Fangzhi Yanjiu, Vol 50, Iss 10, Pp 1015-1021 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1000-8578 |
| DOI: |
10.3971/j.issn.1000-8578.2023.23.0106 |
| Popis: |
Ovarian cancer is one of the common tumors in female reproductive organs and accounts for about 4% of all malignant tumors in women. It is also the leading cause of death among various gynecological tumors. Surgery combined with chemotherapy is the frequently used treatment for ovarian. Chemotherapy resistance is one of the main reasons for the recurrence and poor prognosis of ovarian cancer. Various components of the MAPK pathway, also known as the RAS-RAF-MEK-ERK signaling cascade, are related to cancer, and ERK1/2 is an indispensable key site in this pathway. Continuous research has found that ERK1/2 is a "ferryman" involved in regulating the occurrence, development, and drug resistance mechanisms of ovarian cancer. This article briefly introduces the activation mechanism and pathway of the ERK1/2 signaling pathway, summarizes its relationship to ovarian cancer, and emphasizes that ERK1/2 inhibitors may be a new treatment strategy with potential advantages in improving poor prognosis in patients with ovarian cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
